External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

<ul><li>Akebia Therapeutics aims to challenge the standard of care for anemia management in chronic kidney disease in the USA</li><li>Despite setbacks with FDA rejection of new drug Vafseo, company holds growth potential</li><li>Aims to have over 75,000 patients prescribed to Vafseo by end of 2026, leading to significant sales growth and operating profit; stock seen as undervalued with potential to reach price target of $5.00+</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Akebia Therapeutics aims to challenge the standard of care for anemia management in chronic kidney disease in the USADespite setbacks with FDA rejection of new drug Vafseo, company holds growth potentialAims to have over 75,000 patients prescribed to Vafseo by end of 2026, leading to significant sales growth and operating profit; stock seen as undervalued with potential to reach price target of $5.00+This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Akebia Therapeutics Inc (AKBA) - Friday, Oct 25, 2024

United States

Akebia Therapeutics, Inc. manufactures biopharmaceutical products. The Company develop and distributes novel therapeutics based on the biology of hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Akebia Therapeutics (AKBA US)

Akebia Therapeutics Inc (AKBA) - Friday, Oct 25, 2024

Despite their challenges, the company's stock is seen as undervalued and has the potential to reach a price target of $5.00+.

Value Investors Club (VIC)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)